BIO Asia-Taiwan 2026
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
BioWorld Analysis and data insight Conferences Financings BIO Asia-Taiwan Cancer Endocrine/metabolic Immune Antibody IPO Asia-Pacific China Japan FDA Policy